FDA approves Jardiance (empagliflozin) for the treatment of adults with chronic kidney disease – Boehringer + Eli Lilly
Boehringer Ingelheim and Eli Lilly and Company announced that the FDA has approved Jardiance (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in estimated glomerular… read more.